BR112013027057A2 - composições e métodos para a estabilização de agentes ativos - Google Patents

composições e métodos para a estabilização de agentes ativos Download PDF

Info

Publication number
BR112013027057A2
BR112013027057A2 BR112013027057-8A BR112013027057A BR112013027057A2 BR 112013027057 A2 BR112013027057 A2 BR 112013027057A2 BR 112013027057 A BR112013027057 A BR 112013027057A BR 112013027057 A2 BR112013027057 A2 BR 112013027057A2
Authority
BR
Brazil
Prior art keywords
vaccine
silk
virus
composition
composition according
Prior art date
Application number
BR112013027057-8A
Other languages
English (en)
Portuguese (pt)
Inventor
David L. Kaplan
Fiorenzo Omenetto
Original Assignee
Trustees Of Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Tufts College filed Critical Trustees Of Tufts College
Publication of BR112013027057A2 publication Critical patent/BR112013027057A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/20—Rubella virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112013027057-8A 2011-04-21 2012-04-23 composições e métodos para a estabilização de agentes ativos BR112013027057A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161477737P 2011-04-21 2011-04-21
US61/477,737 2011-04-21
PCT/US2012/034643 WO2012145739A1 (en) 2011-04-21 2012-04-23 Compositions and methods for stabilization of active agents

Publications (1)

Publication Number Publication Date
BR112013027057A2 true BR112013027057A2 (pt) 2020-08-11

Family

ID=47041958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013027057-8A BR112013027057A2 (pt) 2011-04-21 2012-04-23 composições e métodos para a estabilização de agentes ativos

Country Status (9)

Country Link
US (3) US20140287043A1 (enExample)
EP (1) EP2699266B1 (enExample)
JP (2) JP6170906B2 (enExample)
CN (2) CN105148285B (enExample)
AU (6) AU2012245198B2 (enExample)
BR (1) BR112013027057A2 (enExample)
CA (1) CA2833879C (enExample)
IL (1) IL228984A0 (enExample)
WO (1) WO2012145739A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2349367A4 (en) 2008-10-09 2013-09-04 Tufts College MODIFIED SILK FILMS WITH GLYCEROL
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
WO2013106822A1 (en) 2012-01-12 2013-07-18 Johnson Jed K Nanofiber scaffolds for biological structures
US9554989B2 (en) 2012-03-20 2017-01-31 Trustees Of Tufts College Silk reservoirs for drug delivery
WO2013155404A1 (en) 2012-04-13 2013-10-17 Trustees Of Tufts College Methods and compositions for preparing a silk microsphere
US10653786B2 (en) 2012-04-25 2020-05-19 Trustees Of Tufts College Silk microspheres and methods for surface lubrication
WO2014127309A1 (en) 2013-02-15 2014-08-21 Tufts University Silk-based nanoimprinting
EP3412682B1 (en) * 2013-03-15 2022-08-31 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
WO2014144971A1 (en) 2013-03-15 2014-09-18 Tufts University Silk water lithography
WO2014152097A1 (en) * 2013-03-15 2014-09-25 Banner Pharmacaps Inc. Silk-based capsules
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
US11009792B2 (en) 2013-03-15 2021-05-18 Tufts University All water-based nanopatterning
ITMI20131255A1 (it) * 2013-07-26 2015-01-27 Ct Tessile Serico Societa Co Nsortile Per A Composizioni farmaceutiche nebulizzabili a base di fibroina per il trattamento di lesioni cutanee
CA2923010C (en) * 2013-09-03 2022-08-30 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
AU2014321277B2 (en) 2013-09-19 2017-07-20 Terumo Corporation Polymer particles
KR102505172B1 (ko) * 2013-09-19 2023-02-28 마이크로벤션, 인코포레이티드 중합체 필름
SG10201907426UA (en) * 2013-09-30 2019-09-27 Evolved By Nature Inc Silk protein fragment compositions and articles manufactured therefrom
WO2015070094A1 (en) 2013-11-08 2015-05-14 Microvention, Inc. Polymer particles
US20170182206A1 (en) * 2014-04-04 2017-06-29 Nanofiber Solutions, Inc. Electrospun biocompatible fiber compositions
AU2015358537B2 (en) 2014-12-02 2021-08-19 Evolved By Nature, Inc. Silk performance apparel and products and methods of preparing the same
US10213378B2 (en) * 2015-03-10 2019-02-26 Sporos Therapeutics, LLC Single dose non-adjuvanted cutaneous tetanus vaccine and uses thereof
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
CN104940981B (zh) * 2015-05-21 2018-11-30 重庆市畜牧科学院 具有生物活性的外用敷料及其制备方法
BR112018000699B1 (pt) 2015-07-14 2023-10-17 Silk Therapeutics, Inc Artigo e método para revestir um material
CN105903027A (zh) * 2016-05-31 2016-08-31 福建傲农生物科技集团股份有限公司 一种常温下长期保存抗生素的方法
WO2017214187A1 (en) * 2016-06-07 2017-12-14 Aridis Pharmaceuticals, Inc. Method for preparation of quick dissolving thin films containing bioactive material with enhanced thermal stability
CN106362223B (zh) * 2016-08-26 2019-05-03 南通纺织丝绸产业技术研究院 多孔丝素蛋白微针给药装置及其制备方法
GB201614799D0 (en) * 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3532093A1 (en) * 2016-09-19 2019-09-04 Vaxess Technologies, Inc. Vaccine formulations with increased stability
KR102162370B1 (ko) 2016-09-28 2020-10-06 테루모 가부시키가이샤 중합체 입자
WO2018081815A2 (en) 2016-10-31 2018-05-03 Sofregen Medical, Inc. Compositions comprising silk fibroin particles and uses thereof
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
EP3688018A4 (en) 2017-09-27 2021-07-07 Evolved by Nature, Inc. SILK COVERED FABRICS, RELATED PRODUCTS AND PREPARATION PROCESSES
WO2019094702A1 (en) 2017-11-10 2019-05-16 Cocoon Biotech Inc. Ocular applications of silk-based products
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
EP3830576A2 (en) * 2018-07-27 2021-06-09 Vaxess Technologies, Inc. Polymer-based biospecimen collection devices and uses thereof
JP7437385B2 (ja) * 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
AU2019395339B2 (en) 2018-12-10 2025-12-11 Cambridge Crops, Inc. Compositions and methods for polymer based shelf life extension
TWI691531B (zh) * 2019-02-11 2020-04-21 南臺學校財團法人南臺科技大學 蠶絲蛋白膜的製造方法
CA3142608A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
CN110627899A (zh) * 2019-10-09 2019-12-31 山东天牧生物科技有限公司 一种呼肠孤病毒和细小病毒卵黄抗体锭及其制备方法
WO2021076798A1 (en) 2019-10-15 2021-04-22 Sofregen Medical, Inc. Delivery devices for delivering and methods of delivering compositions
CN114727904A (zh) * 2019-11-18 2022-07-08 礼蓝美国公司 在直壁小瓶中的冻干饼块
US20230285536A1 (en) * 2020-06-24 2023-09-14 Trustees Of Tufts College Edible cell based vaccines
EP4256958A1 (en) * 2020-11-13 2023-10-11 Targetalent, Lda Composition for cryopreservation of biological samples for pcr
GB2615462A (en) * 2020-11-20 2023-08-09 Team Medical Llc RNA stabilization
WO2022187346A1 (en) * 2021-03-02 2022-09-09 Georgia Tech Research Corporation Hydrogel materials and methods of making and transport using the same
US11976196B2 (en) 2021-04-14 2024-05-07 Cambridge Crops, Inc. Silk packaging applications
EP4149277A4 (en) 2021-05-21 2024-11-20 Cambridge Crops, Inc. d/b/a Mori SYSTEMS AND METHODS FOR MANUFACTURING SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROIN
US11864569B2 (en) 2021-08-16 2024-01-09 Cambridge Crops, Inc. Systems and methods for improving the performance of cereal using a silk fibroin solution and powders containing silk fibroin
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用
US20250223571A1 (en) 2022-03-30 2025-07-10 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material
CN115227863A (zh) * 2022-07-01 2022-10-25 浙江大学 一种搭载噬菌体的复合水凝胶及其制备方法
WO2024095794A1 (ja) * 2022-10-31 2024-05-10 国立研究開発法人農業・食品産業技術総合研究機構 フィブロイン含有ナノ粒子を含む経口投与型ワクチン用組成物

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808A (en) 1852-03-16 Planiwg-machiete
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
JPH0652268B2 (ja) * 1985-07-03 1994-07-06 鐘紡株式会社 固定化抗原
CN86100565A (zh) * 1986-04-30 1987-11-11 华东化工学院 一种共价活化的固定化酶载体
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL86180A (en) 1987-05-04 1992-08-18 Merck & Co Inc Stable lyophilized live herpes virus vaccine and such a vaccine combined with other virus vaccines
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2750306B2 (ja) * 1989-05-24 1998-05-13 ポーラ化成工業株式会社 固定化低分子プロテインａの製造法
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5346481A (en) 1993-10-14 1994-09-13 Merck & Co., Inc. Vaccine delivery system
US5900238A (en) 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
JPH11511325A (ja) 1995-08-22 1999-10-05 アグリコラ・テクノロジーズ・インコーポレイテツド 高力クモシルク蛋白質のクローニング方法
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
AU725231B2 (en) * 1996-12-20 2000-10-12 Merck & Co., Inc. Stabilisers for lyophilised vaccines
JP3101711B2 (ja) * 1997-11-20 2000-10-23 農林水産省蚕糸・昆虫農業技術研究所長 生体高分子からなる吸着体／徐放体及びその製造方法
EP1210064B1 (en) 1999-08-18 2005-03-09 Microchips, Inc. Thermally-activated microchip chemical delivery devices
DE60041825D1 (de) 1999-11-17 2009-04-30 Boston Scient Ltd Miniaturisierte vorrichtungen zur abgabe von molekülen in einer trägerflüssigkeit
DE60219607T2 (de) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
RU21271U1 (ru) * 2001-08-06 2002-01-10 Алкацева Надежда Ильинична Основа для косметических средств
AR040819A1 (es) 2002-08-08 2005-04-20 Alza Corp Dispositivo de administracion transdermica de vacuna que tiene microproyecciones revestidas
JP2005097229A (ja) * 2002-12-04 2005-04-14 Toray Ind Inc ワクチンおよび抗原タンパク質の製造方法
WO2004062697A2 (en) 2003-01-07 2004-07-29 Tufts University Silk fibroin materials and use thereof
US7060260B2 (en) * 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
WO2005012606A2 (en) 2003-04-10 2005-02-10 Tufts University Concentrated aqueous silk fibroin solution and use thereof
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
JP2007509704A (ja) 2003-10-31 2007-04-19 アルザ・コーポレーシヨン 経皮的ワクチン送達のための系および方法
KR20070011252A (ko) 2003-11-21 2007-01-24 알자 코포레이션 초음파 보조 경피 백신전달방법 및 시스템
CN1243059C (zh) * 2004-03-04 2006-02-22 苏州大学 纳米丝素颗粒的制造方法
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2006076711A2 (en) 2005-01-14 2006-07-20 Trustees Of Tufts College Fibrous protein fusions and use thereof in the formation of advanced organic/inorganic composite materials
EP1915436B1 (en) * 2005-08-02 2011-09-28 Trustees Of Tufts College Methods for stepwise deposition of silk fibroin coatings
US20090182306A1 (en) * 2006-07-21 2009-07-16 Georgia Tech Research Corporation Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal
US20100028451A1 (en) 2006-09-26 2010-02-04 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
JP2010508852A (ja) 2006-11-03 2010-03-25 トラスティーズ オブ タフツ カレッジ 電気活性バイオポリマー光学デバイスおよび電気活性バイオポリマー電気光学デバイスならびにその製造方法
CA2704768A1 (en) * 2006-11-03 2008-10-23 Trustees Of Tufts College Biopolymer sensor and method of manufacturing the same
US8911749B2 (en) * 2007-04-16 2014-12-16 Corium International, Inc. Vaccine delivery via microneedle arrays
JP2010529230A (ja) 2007-05-29 2010-08-26 トラスティーズ オブ タフツ カレッジ 音波処理を用いた絹フィブロインのゲル化のための方法
US20090142836A1 (en) * 2007-11-28 2009-06-04 Organogenesis, Inc. Bioengineered tissue constructs and methods for production and use
US8206774B2 (en) 2008-03-13 2012-06-26 Trustees Of Tufts College Diazonium salt modification of silk polymer
US8501172B2 (en) 2008-09-26 2013-08-06 Trustees Of Tufts College pH-induced silk gels and uses thereof
EP2349367A4 (en) 2008-10-09 2013-09-04 Tufts College MODIFIED SILK FILMS WITH GLYCEROL
US9427499B2 (en) 2008-11-17 2016-08-30 Trustees Of Tufts College Surface modification of silk fibroin matrices with poly(ethylene glycol) useful as anti-adhesion barriers and anti-thrombotic materials
WO2010141133A2 (en) * 2009-03-04 2010-12-09 Trustees Of Tufts College Silk fibroin systems for antibiotic delivery
WO2011005381A2 (en) 2009-06-01 2011-01-13 Trustees Of Tufts College Vortex-induced silk fibroin gelation for encapsulation and delivery
US8293486B2 (en) 2009-07-21 2012-10-23 Trustees Of Tufts College Functionalization of silk material by avidin-biotin interaction
IN2012DN02358A (enExample) * 2009-09-29 2015-08-21 Tufts College
JP5937092B2 (ja) * 2010-10-19 2016-06-22 トラスティーズ オブ タフツ カレッジ シルクフィブロインベースのマイクロニードルおよびその製造方法
CN102085173B (zh) * 2011-01-26 2012-05-30 上海交通大学 以天然蚕丝蛋白为乳化剂的生物活性乳液及其制备方法
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物

Also Published As

Publication number Publication date
US20140287043A1 (en) 2014-09-25
CN103796683A (zh) 2014-05-14
AU2017204162A1 (en) 2017-07-27
EP2699266A1 (en) 2014-02-26
EP2699266B1 (en) 2019-06-12
AU2020217419A1 (en) 2020-09-17
CA2833879C (en) 2023-03-14
AU2018226377A1 (en) 2018-09-27
AU2020203212A1 (en) 2020-06-11
IL228984A0 (en) 2013-12-31
US20170258889A1 (en) 2017-09-14
JP6170906B2 (ja) 2017-07-26
US12280101B2 (en) 2025-04-22
AU2012245198B2 (en) 2017-07-13
AU2012245198A1 (en) 2013-11-07
AU2022235540A1 (en) 2022-10-20
AU2018226377B2 (en) 2020-09-03
WO2012145739A1 (en) 2012-10-26
CN105148285B (zh) 2019-02-12
CA2833879A1 (en) 2012-10-26
JP2014518557A (ja) 2014-07-31
JP2017137328A (ja) 2017-08-10
EP2699266A4 (en) 2014-12-24
CN105148285A (zh) 2015-12-16
US20180360947A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
AU2018226377B2 (en) Compositions and methods for stabilization of active agents
JP2022089818A (ja) 融合前ｒｓｖ ｆタンパク質およびそれらの使用
JP5937092B2 (ja) シルクフィブロインベースのマイクロニードルおよびその製造方法
JP2023527175A (ja) ワクチン放出のための組成物およびデバイスならびにそれらの使用
Nguyen et al. Skin immunization with third-generation hepatitis B surface antigen using microneedles
CN108743938B (zh) 用于增强免疫响应的复合物的制备方法
US9782475B2 (en) Method of treating food allergies by administering a nanoparticle comprising heparin and chitosan encapsulating IL-12
US20060177468A1 (en) Delivery vehicles, bioactive substances and viral vaccines
Williamson et al. Clinical and preclinical methods of heat-stabilization of human vaccines
CN104302317A (zh) 新型和改进的流感疫苗
Zhang et al. Nanoparticle-based vaccines against zoonotic viruses: a review
WO2023194699A2 (en) Vaccine composition
HK1197999A (en) Compositions and methods for stabilization of active agents
WO2024158849A1 (en) Compositions and methods of use for stabilizing and delivery of atomic layer deposition coating of agent-containing lipid-emulsion formulations
Haughney Polyanhydride nanovaccine platform against bacterial pathogens
Mistilis THERMOSTABILIZATION OF INFLUENZA VACCINE IN MICRONEEDLE PATCHES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]